arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Monopar Therapeutics

MNPR

$67.26 ▼ -4.57 (-6.36%) at close

11 Visible periods

20 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Neutral

auto_awesome

Analytical Summary

Monopar Therapeutics shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $498.5M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -12.1% ↗

FCF / Share $-1.65 ↗

Trailing P/E —

Price / Book 3.3x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

11-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-13.72M

↑ +12.0% —

FCF / Share Free cash flow per share

$-1.65

↑ +2.6% —

Health Breakdown

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
EPS Growth YoY (%)	55.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-573.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	26.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	12.0% Fair ↑ Fair Improving Year-over-year change in net income	-85.5% Weak ↓ Weak Declining Year-over-year change in net income	20.1% Good ↑ Good Improving Year-over-year change in net income	-15.5% Weak ↑ Weak Improving Year-over-year change in net income	-44.4% Weak ↓ Weak Declining Year-over-year change in net income	-49.2% Weak ↑ Weak Improving Year-over-year change in net income	-30.9% Weak ↑ Weak Improving Year-over-year change in net income	80.5% Excellent Excellent Year-over-year change in net income	-1296.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	2.6% Caution ↑ Caution Improving Year-over-year change in free cash flow	-197.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	-0.0% Weak Weak Year-over-year change in free cash flow	3.1% Caution Caution Year-over-year change in free cash flow	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Effective Tax Rate (%) (%)	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	2.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
FCF / Net Income (x)	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.41x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.16x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Return on Invested Capital (%)	-12.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-29.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-124.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-82.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-38.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-32.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-27.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-48.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-172.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-33.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-11.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-26.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-120.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-79.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-44.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-38.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-32.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-46.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-167.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-41.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-10.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-166%)	-28.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-289%)	-150.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1102%)	-104.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-795%)	-48.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-420%)	-40.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-368%)	-33.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-323%)	-46.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-411%)	-172.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1247%)	-41.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-379%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Net Debt (USD)	$-61.83M	$-45.82M	$-7.27M	$-8.19M	$-20.30M	$-16.74M	$-13.21M	$-6.89M	$-8.98M	$-2.07M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Revenue per Share (USD)	$0.00	—	$0.00	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-1.85	$-4.11	$-0.61	$-0.83	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-1.65	$-1.69	$-0.57	$-0.57	$-0.59	—	—	—	—	—	—
Book Value per Share (USD)	$20.60	$9.02	$0.37	$0.78	$1.50	$1.37	$1.19	$0.74	$1.04	—	—
Tangible Book Value per Share (USD)	$20.60	$9.02	$0.37	$0.78	$1.50	$1.37	$1.19	$0.74	$1.04	—	—
Basic Weighted Avg Shares (shares)	7.41M	3.79M	13.82M	12.72M	12.47M	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Working Capital (USD)	$137.73M	$55.04M	$5.58M	$10.04M	$18.94M	$15.62M	$12.51M	$6.92M	$8.82M	$2.03M	—
Total Equity (USD)	$137.83M	$55.04M	$5.59M	$10.09M	$18.94M	$15.69M	$12.63M	$6.92M	$9.62M	$2.83M	$2.75M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	—	$0.00	—	—	—	—	$0.00	$0.00	$0.00	—
Net Income, GAAP (USD)	$-13.72M	$-15.59M	$-8.40M	$-10.52M	$-9.10M	$-6.30M	$-4.22M	$-3.23M	$-16.55M	$-1.19M	—
Operating Cash Flow (USD)	$-12.20M	$-6.40M	$-7.86M	$-7.23M	$-7.32M	$-4.66M	$-3.02M	$-2.89M	$-2.63M	$-1.19M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 11 years · 40 quarters

Monopar Therapeutics

Analytical Summary

11-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare MNPR with peers